Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 1;7(8):1133-1140.
doi: 10.1001/jamaoncol.2021.2155.

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh  1 , Noa Eliakim-Raz  2   3   4 , Amos Stemmer  4 , Adva Levy-Barda  5 , Shlomit Yust-Katz  4   6 , Alona Zer  1   4 , Alexandra Benouaich-Amiel  1 , Haim Ben-Zvi  4   7 , Neta Moskovits  8 , Baruch Brenner  1   4 , Jihad Bishara  3   4 , Dafna Yahav  3   4 , Boaz Tadmor  9 , Tal Zaks  10 , Salomon M Stemmer  1   4   8
Affiliations

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh et al. JAMA Oncol. .

Abstract

Importance: Patients with cancer undergoing treatment are at high risk of COVID-19 following SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to messenger RNA SARS-CoV-2 vaccines is unclear.

Objective: To evaluate rates of antispike (anti-S) antibody response to a BNT162b2 vaccine in patients with cancer who are undergoing systemic treatment vs healthy controls.

Design, setting, and participants: This prospective cohort study included 102 adult patients with solid tumors undergoing active intravenous anticancer treatment and 78 controls who received the second dose of the BNT162b2 vaccine at least 12 days before enrollment. The controls were taken from a convenience sample of the patients' family/caregivers who accompanied them to treatment. The study was conducted between February 22, 2021, and March 15, 2021 at Davidoff Cancer Center at Beilinson Hospital (Petah Tikva, Israel).

Interventions: Blood samples were drawn from the study participants. Serum samples were analyzed and the titers of the IgG antibodies against SARS-CoV-2 spike receptor-binding domain were determined using a commercially available immunoassay. Seropositivity was defined as 50 or greater AU/mL.

Main outcomes and measures: The primary outcome was the rate of seropositivity. Secondary outcomes included comparisons of IgG titers and identifying factors that were associated with seropositivity using univariate/multivariable analyses.

Results: The analysis included 180 participants, which comprised 102 patients with cancer (median [interquartile range (IQR)] age, 66 [56-72] years; 58 men [57%]) and 78 healthy controls (median [IQR] age, 62 [49-70] years; 25 men [32%]). The most common tumor type was gastrointestinal (29 [28%]). In the patient group, 92 (90%) were seropositive for SARS-CoV 2 antispike IgG antibodies after the second vaccine dose, whereas in the control group, all were seropositive. The median IgG titer in the patients with cancer was significantly lower than that in the controls (1931 [IQR, 509-4386] AU/mL vs 7160 [IQR, 3129-11 241] AU/mL; P < .001). In a multivariable analysis, the only variable that was significantly associated with lower IgG titers was treatment with chemotherapy plus immunotherapy (β, -3.5; 95% CI, -5.6 to -1.5).

Conclusions and relevance: In this cohort study of patients with cancer who were receiving active systemic therapy, 90% of patients exhibited adequate antibody response to the BNT162b2 vaccine, although their antibody titers were significantly lower than those of healthy controls. Further research into the clinical relevance of lower titers and their durability is required. Nonetheless, the data support vaccinating patients with cancer as a high priority, even during therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Yust-Katz reported grants from MSD and personal fees from Honorarium Teva, Novartis, Novocure, and AstraZeneca outside the submitted work. Dr Zer reported personal fees from Roche, AstraZeneca, MSD, and Takeda as well as grants from BMS outside the submitted work. Dr Zaks reported personal fees from Moderna outside the submitted work. Dr S. M. Stemmer received research grants (to the institution) from CANFITE, AstraZeneca, Bioline RX, BMS, Halozyme, Clovis Oncology, CTG Pharma, Exelexis, Geicam, Incyte, Lilly, Moderna, Teva Pharmaceuticals, and Roche and owns stocks and options in CTG Pharma, DocBoxMD, Tyrnovo, VYPE, Cytora, and Canfite. No other disclosures were reported.

Figures

Figure.
Figure.. IgG Values
B and C, Greyed areas represent 95% CIs.
See this image and copyright information in PMC

Comment in

References

    1. Zhu N, Zhang D, Wang W, et al. ; China Novel Coronavirus Investigating and Research Team . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Worldometer . Coronavirus update (live): 123,438,047 cases and 2,722,111 deaths from COVID-19 virus pandemic. Accessed March 21, 2021. https://www.worldometers.info/coronavirus
    1. Robilotti EV, Babady NE, Mead PA, et al. . Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-1223. doi:10.1038/s41591-020-0979-0 - DOI - PMC - PubMed
    1. Rugge M, Zorzi M, Guzzinati S.. SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nat Cancer. 2020;1(8):784-788. doi:10.1038/s43018-020-0104-9 - DOI - PubMed
    1. Saini KS, Tagliamento M, Lambertini M, et al. . Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50. doi:10.1016/j.ejca.2020.08.011 - DOI - PMC - PubMed

MeSH terms